Bharat Parenterals Limited

BPLPHARMA6

INE365Y01019

Pharmaceuticals

Market Closed - Bombay S.E. Other stock markets 03:30:56 01/07/2024 pm IST			5-day change	1st Jan Change
1,500 ^INR	+0.60%		+3.88%	+85.16%

24/06	Bharat Parenterals Limited agreed to acquire an unknown majority stake in Varenyam Biolifesciences Private Limited for INR 22.56 million.	CI
06/06	Bharat Parenterals to Raise Stake in Subsidiary Innoxel Lifesciences	MT

Bharat Parenterals Limited Appoints Jignesh Shah as Chief Financial Officer

August 14, 2018 at 05:50 pm IST

Bharat Parenterals Limited at their meeting held on August 14, 2018 approved appointment of Mr. Jignesh Shah as Chief Financial Officer and Key Managerial Personnel of the Company with effect from 14 August, 2018.

Latest news about Bharat Parenterals Limited

Bharat Parenterals Limited agreed to acquire an unknown majority stake in Varenyam Biolifesciences Private Limited for INR 22.56 million.	24/06	CI
Bharat Parenterals to Raise Stake in Subsidiary Innoxel Lifesciences	06/06	MT
Bharat Parenterals Limited agreed to acquire an additional 4.89% stake in Innoxel Lifesciences Private Limited for approximately INR 650.	05/06	CI
Bharat Parenterals Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2024	22/05	CI
Bharat Parenterals Limited Reports Earnings Results for the Full Year Ended March 31, 2024	22/05	CI
Bharat Parenterals Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	13/02	CI
Bharat Parenterals Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	09/11	CI
Bharat Parenterals Limited Appoints Krutika Padmakar Bhattbhatt as Company Secretary and Compliance Officer	02/23/02	CI
Bharat Parenterals Limited Announces Resignation of Shyam Singh Rajpurohit as Company Secretary and Compliance Officer	02/23/02	CI
Bharat Parenterals Limited Declares Dividend for the Financial Year 2022 to 2023	30/23/30	CI
Bharat Parenterals Limited Reports Earnings Results for the First Quarter Ended June 30, 2023	09/23/09	CI
Bharat Parenterals Limited Recommends Final Dividend for the Financial Year Ended March 31, 2023	07/23/07	CI
Bharat Parenterals Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2023	20/23/20	CI
Bharat Parenterals Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022	13/23/13	CI
Bharat Parenterals Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2022	12/22/12	CI
Bharat Parenterals Limited Reports Earnings Results for the First Quarter Ended June 30, 2022	10/22/10	CI
Bharat Parenterals Forms New Unit	17/22/17	MT
Bharat Parenterals Limited Reports Earnings Results for the Full Year Ended March 31, 2022	28/22/28	CI
Bharat Parenterals Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2022	28/22/28	CI
Bharat Parenterals Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2021	09/22/09	CI
Bharat Parenterals Limited Announces Change in Registered Office Address	04/22/04	CI
Bharat Parenterals Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2021	30/21/30	CI
Bharat Parenterals Limited Reports Earnings Results for the First Quarter Ended June 30, 2021	11/21/11	CI
Bharat Parenterals' : Consolidated Profit Plunges in Fiscal Q4	07/21/07	MT
Bharat Parenterals Limited Announces Audited Standalone and Consolidated Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2021	05/21/05	CI

Chart Bharat Parenterals Limited

Duration

Period

More charts

Company Profile

Bharat Parenterals Limited is an India-based pharmaceutical company. The Company is engaged in manufacturing of pharmaceutical formulations. The Company is engaged in research, development, manufacturing, marketing, sourcing and distribution of pharmaceutical products. The Company offers a range of products, including B-lactam antibiotics, anti-retroviral, cephalosporins antibiotics, antiprotozoal / anthelmintic, respiratory, antiallergic / anti histaminic / anticold, cleansing agents/skin infections, antibiotic, cardiovascular system, anti-diabetic, anti-tuberculosis, anti-fungal, antimalarial, gastroinestinaltract / alimentary system, anti-inflammatory / anti pyretic / analgesic, supplements, central nervous system, anesthetics, anti-viral, steroids and hormones, uterine stimulant, anticancer and other. Its clients range from small biopharmaceutical startups to some pharmaceutical companies.

Sector

Pharmaceuticals

Calendar

02/07/2024 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
BHARAT PARENTERALS LIMITED	+85.16%	117M
ELI LILLY AND COMPANY	+55.32%	815B
NOVO NORDISK A/S	+43.17%	641B
JOHNSON & JOHNSON	-6.75%	352B
MERCK & CO., INC.	+13.56%	314B
ABBVIE INC.	+10.68%	303B
ASTRAZENECA PLC	+16.15%	242B
ROCHE HOLDING AG	+1.96%	224B
NOVARTIS AG	+13.36%	218B
AMGEN INC.	+8.48%	168B